Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus

Abstract

© 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. This is the protocol for a review and there is no abstract. The objectives are as follows: To assess the effects of insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. Secondary objectives are to analyse the strength and quality of the body of evidence for the associations between various definitions of risk (impaired glucose tolerance, impaired fasting glucose, HbA1c thresholds) and the therapeutic consequences of insulin secretagogues. Due to the current very limited use of first-generation sulphonylureas, we will not include this class of sulphonylureas in our review.